Paul Chapman is an Oncology physician. ClinicalTrials.gov lists 16 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1305 York Ave Fl 12
New York, NY 100215663
Telephone
646-962-6444Provider last certified this registry record 21 May 2025.
Clinical trials
- Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade
Sponsor: Weill Medical College of Cornell University
- A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery
Sponsor: Memorial Sloan Kettering Cancer Center
- Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma
Sponsor: Memorial Sloan Kettering Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Exelixis Inc.Program year20251 payment
- PFIZER INC.Program year20241 payment
- Iovance Biotherapeutics, Inc.Program year20242 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
6 NIH research awards on record, funded 1992–2007 per NIH RePORTER. The latest:
- Phase II trial of 17-AAG in melanoma patients
Sloan-Kettering Inst Can Research
FY2007$344,232R21CA112899 - Phase II trial of 17-AAG in melanoma patients
Sloan-Kettering Inst Can Research
FY2006$379,836R21CA112899 - Anti-GD3 NKT cells as effector cells against melanoma
Sloan-Kettering Inst Can Research
FY2006$273,548R01CA097041
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”